Time-dependent Cox proportional hazards models for any organ damage for inception cohort (patients within the 1st year of diagnosis (N=642) and patients within the 2nd year of diagnosis (N=944))
| Model 4 (N=642) | Model 5 (N=944) | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Age at cohort entry | 1.043 (1.031 to 1.056) | <0.001 | 1.037 (1.027 to 1.047) | <0.001 |
| Sex (female vs male) | 1.033 (0.674 to 1.583) | 0.882 | 1.069 (0.759 to 1.506) | 0.702 |
| Race | ||||
| Black (vs White) | 1.067 (0. 809 to 1.407) | 0.647 | 1.140 (0.911 to 1.426) | 0.253 |
| Asian (vs White) | 1.041 (0.455 to 2.383) | 0.924 | 0. 734 (0.324 to 1.663) | 0.459 |
| Other (vs White) | 1.176 (0.468 to 2.957) | 0.730 | 1.366 (0.726 to 2.569) | 0.334 |
| Year of SLE diagnosis | 0.979 (0.957 to 1.003) | 0.080 | 0.986 (0.967 to 1.006) | 0.164 |
| SDI at cohort entry | 1.043 (0.943 to 1.155) | 0.411 | 1.050 (0.968 to 1.140) | 0.241 |
| SELENA-SLEDAI score during follow-up (≥6 vs <6) | 1.382 (0.960 to 1.989) | 0.082 | 1.328 (0.986 to 1.789) | 0.062 |
| Immunosuppressant use during follow-up (yes vs no) | 1.326 (0.969 to 1.815) | 0.078 | 1.424 (1.103 to 1.837) | 0.007 |
| Antimalarial use during follow-up (yes vs no) | 0.916 (0.698 to 1.201) | 0.525 | 0.923 (0.734 to 1.160) | 0.491 |
| Mean prednisone dose, mg/day (≥7.5 vs <7.5) | 1.834 (1.339 to 2.512) | <0.001 | 1.730 (1.338 to 2.236) | <0.001 |
NA, not applicable; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index; SLE, systemic lupus erythematosus.